Chemomab Therapeutics Ltd DRC (CMMB)

NASDAQ
2.57
+0.21(+8.90%)
After Hours
2.58
+0.01(+0.39%)
- Real-time Data
  • Volume:
    22,705
  • Day's Range:
    2.33 - 2.60
  • 52 wk Range:
    2.25 - 13.19

CMMB Overview

Prev. Close
2.36
Day's Range
2.33-2.6
Revenue
-
Open
2.33
52 wk Range
2.25-13.19
EPS
-1.69
Volume
22,705
Market Cap
29.38M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
38,429
P/E Ratio
-1.63
Beta
1.64
1-Year Change
-80.7%
Shares Outstanding
11,431,656
Next Earnings Date
Nov 11, 2022
What is your sentiment on Chemomab Therapeutics DRC?
or
Market is currently closed. Voting is open during market hours.

Chemomab Therapeutics Ltd DRC News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Chemomab Therapeutics Ltd DRC Company Profile

Chemomab Therapeutics Ltd DRC Company Profile

Employees
0

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company’s lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Read More

Analyst Price Target

Average22.00 (+756.03% Upside)
High25
Low20
Price2.57
No. of Analysts3
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralSellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell
  • 7.8 first stop
    0
    • 20 soon
      0
      • what happened? why suddenly up?
        0
        • Merger was approved by shareholders last night
          1
      • The merger will create a company focused on advancing Chemomab’s lead product, CM-101, for the treatment of fibrosis-related diseases.
        0
        • This should be a great marriage going forward
          0
          • I wish.. any facts?
            0
          • Facts are in the merger report that are in the news, that made my conclusion. Research on your own and state your conclusions. To each their own...It's you money invest wisely, make your own conclusions.
            1
        • Bo0om
          0
          • i really dislike isreal stocks, from what ive seen they've never ended well for shareholders
            1